Oligonucleotide and RNAi Therapeutics

The Oligonucleotide and RNAi Therapeutics committee develops ASGCT programming related to the latest developments and advances in the oligonucleotide therapeutics area from discovery to clinical applications, including new chemistry, novel targeted delivery approaches, and therapeutic applications. The committee focus also includes, but is not limited to, challenges in oligonucleotide therapeutics including toxicity and clinical development as well as emerging scientific areas that are amenable or relevant to oligonucleotide therapeutic modalities including ASOs, RNAi, aptamers, circular RNAs, RNA editing, mRNAs, and tRNAs.
Full NamePositionOrganizationTerm StartTerm End
Marcin Kortylewski, PhDChairCity of Hope Comprehensive Cancer Center6/1/20255/31/202722260
Hernando Lopez-Bertoni, PhDMemberJohns Hopkins School Of Medicine6/1/20245/31/202742122
Andrew Coles, PhDMemberAbbVie6/1/20245/31/202740459
Isabel AznarezMemberStoke Therapeutics6/1/20255/31/202831999
Marcin Kortylewski, PhDMemberCity of Hope Comprehensive Cancer Center6/1/20245/31/202722260
Janaiah Kota, Executive DirectorMemberUltragenyx Pharmaceutical Inc.6/1/20245/31/202715768
Nizar Y. Saad, PhDMemberThe Ohio State University and Nationwide Children's Hospital6/1/20255/31/202833359
Keith GagnonMemberWake Forest University School of Medicine6/1/20255/31/202872736
Prashant Monian, PhDMemberWave Life Sciences6/1/20235/31/202945091
Gerard Platenburg, PhDMemberProQR Therapeutics B.V.6/1/20265/31/202923441
Jonathan K. Watts, PhDMemberUMass Chan Medical School6/1/20255/31/202827373
Liubov V. Gushchina, PhDMemberThe Ohio State University and Nationwide Children's Hospital RI6/1/20235/31/202936042
Mehar Gayatri Devi NamalaMemberUCSF6/1/20265/31/2029105354
Danielle GaleStaff LiaisonASGCT6/1/20215/31/204535359